×

img Acces sibility Controls

Research Projects Banner

Research Projects

Synthesis and evaluation of novel dual GSK-3β/HDAC inhibitor as an anti-Alzheimer agent

Implementing Organization

Principal Investigator
Dr. Abha Sharma
Associate Professor
|
National Institute of Pharmaceutical Education and Research, Raebareli

Project Overview

Alzheimer's disease (AD) is a multifactorial neurodegenerative disorder with an expected number of 152 million people by 2050. A multi-target strategy is considered effective for designing new molecules to modulate AD's interconnected targets. A dual classical GSK-3β/epigenetic HDAC6 inhibitor is designed for synthesis and biological study. Preliminary in silico studies show promising properties, binding affinity, and toxicity profile. The proposed four multistep schemes will synthesize the molecules, with the aim of discovering lead molecules for AD treatment. This research area is limited to one international study and no report from India.
Funding Organization
Funding Organization

Quick Information
Area of Research
Pharmaceutical Sciences
Focus Area
Medicinal Chemistry, life sciences
Start Year
2023
Sanction Amount
₹ 37.31 L
Status
Ongoing
Output
No. of Research Paper
00
Technologies (If Any)
00
No. of PhD Produced
N/A
Startup (If Any)
00
No. of Patents
Filed :00
Grant :00
arrowtop